Redmile Group and Blast led a €15m Series A funding round in One Biosciences.

Redmile Group, an investment management firm, and Blast, a Paris-based investment club and venture capital firm, led a €15m Series A funding round in One Biosciences, a precision oncology tech bio company, with participation from Galion.exe, Invus, Adamed Technology, Sofinnova Partners, Polytechnique Ventures, and Kima Ventures. “This funding enables us to translate our breakthrough single-cell technology into real-time insights that could directly inform physician decision-making, improve patient care, and accelerate drug development. The extraordinary support we have received from this group of leading global investors reinforces our conviction and fast-tracks our route to market,” Hedi Ben Brahim, One Biosciences CEO.